{
  "paper_metadata": {
    "pmid": "23974642",
    "title": "MAIN TEXT",
    "extraction_summary": "The paper discusses the effects of tafamidis on patients with the Val30Met mutation in the TTR gene, focusing on its long-term safety, tolerability, and efficacy. No other TTR variants are mentioned."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 86,
        "demographics": "Men and women with TTR-FAP, median age 37.5 years in tafamidis group, 36.0 years in placebo group",
        "phenotype": "Transthyretin familial amyloid polyneuropathy (TTR-FAP)"
      },
      "penetrance_data": {
        "total_carriers_observed": 86,
        "affected_count": null,
        "unaffected_count": null,
        "uncertain_count": null,
        "penetrance_percentage": null,
        "age_dependent_penetrance": []
      },
      "individual_records": [],
      "functional_data": {
        "summary": "Tafamidis stabilizes the TTR tetramer, slowing disease progression.",
        "assays": [
          "Immunoturbidimetric assay for TTR stabilization"
        ]
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "high",
      "source_location": "Abstract, Introduction, Methods",
      "additional_notes": "The study focuses on the Val30Met mutation and its response to tafamidis treatment.",
      "key_quotes": [
        "Tafamidis, a transthyretin (TTR) kinetic stabilizer, delayed neuropathic progression in patients with Val30Met TTR familial amyloid polyneuropathy (TTR-FAP).",
        "Men and women who had TTR-FAP with the Val30Met mutation and completed the month 18 visit of study Fx-005 were eligible."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Baseline demographic and disease characteristics (intent-to-treat population)",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [
      "No other TTR variants besides Val30Met were mentioned."
    ],
    "notes": "The paper primarily discusses the Val30Met variant in the context of tafamidis treatment."
  }
}